Role of adalimumab in the management of children and adolescents with juvenile idiopathic arthritis and other rheumatic conditions
Katherine Anne B MarzanDivision of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, USAAbstract: Treatment of children and adolescents with juvenile idiopathic arthritis and other pediatric rheumatic diseases has evolved. Where once there was only a limited arsenal of medicati...
Saved in:
| Main Author: | |
|---|---|
| Format: | Book |
| Published: |
Dove Medical Press,
2012-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Katherine Anne B MarzanDivision of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, USAAbstract: Treatment of children and adolescents with juvenile idiopathic arthritis and other pediatric rheumatic diseases has evolved. Where once there was only a limited arsenal of medications, with significant side effects and inadequate efficacy, today, with an increased understanding of the pathogenesis of these diseases, there is a wider variety of more targeted and effective treatments. TNF-α is a cytokine involved in a number of inflammatory pathways in pediatric rheumatic diseases. The emergence of biologic modifiers that target TNF-α has been pivotal in providing the ability to deliver early and aggressive treatment. Adalimumab, a recombinant monoclonal antibody to TNF-α, is an important therapeutic option, which affords children and adolescents with chronic illnesses an improved quality of life.Keywords: adalimumab, juvenile idiopathic arthritis, TNF-α, pediatric, rheumatic diseases, treatment |
|---|---|
| Item Description: | 1179-318X |